CD40LG and mantle cell lymphoma: In primary MCL cells, co-cultured with CD40L-expressing fibroblasts, KIN-8194 reduced the ATP-activity in all 5 tested patient samples, with a mean inhibition of 51% after treatment with 100 nM KIN-8194, whereas ibrutinib treatment only marginally affected 3 out of 5 samples, even at a relatively high concentration of 316 nM (Fig. 1E).